@prefix this: . @prefix sub: . @prefix beldoc: . @prefix rdfs: . @prefix rdf: . @prefix xsd: . @prefix dct: . @prefix dce: . @prefix pav: . @prefix np: . @prefix belv: . @prefix prov: . @prefix schem: . @prefix pfh: . @prefix proteinModification: . @prefix psimod: . @prefix mesh: . @prefix occursIn: . @prefix species: . @prefix pubmed: . @prefix orcid: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { sub:_1 belv:variantOf pfh:AKT%20Family; a proteinModification:, psimod:00696 . sub:_2 occursIn: mesh:D001853, species:9606; rdf:object sub:_1; rdf:predicate belv:decreases; rdf:subject schem:LY%20294002; a rdf:Statement . sub:assertion rdfs:label "a(SCHEM:\"LY 294002\") -| p(PFH:\"AKT Family\",pmod(P))" . } sub:provenance { beldoc: dce:description "Approximately 61,000 statements."; dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved."; dce:title "BEL Framework Large Corpus Document"; pav:authoredBy sub:_4; pav:version "1.4" . sub:_3 prov:value "Inhibition of PI3K resulted in a dose-dependent inhibition of RUNX2 activity with 30, 50, and 90% inhibition at LY294002 concentrations of 5, 10, and 20 µM, respectively. RUNX2 protein levels were also reduced, as was pAkt."; prov:wasQuotedFrom pubmed:15304489 . sub:_4 rdfs:label "Selventa" . sub:assertion prov:hadPrimarySource pubmed:15304489; prov:wasDerivedFrom beldoc:, sub:_3 . } sub:pubinfo { this: dct:created "2014-07-03T14:30:26.730+02:00"^^xsd:dateTime; pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 . }